AstraZeneca (LSE:AZN) has agreed a new five year national partnership with YMCA of the USA to expand community based cancer education, screening, and survivorship support. The company also received US ...

FDA grants Priority Review to AstraZeneca’s Imfinzi sBLA for muscle-invasive bladder cancer, with decision expected in Q2 2025. Imfinzi regimen showed a 32% reduced risk of disease progression and a ...

AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus placebo.

Add Yahoo as a preferred source to see more of our stories on Google. AstraZeneca's cancer medicine Imfinzi (Reuters) -AstraZeneca said on Thursday the U.S. Food and Drug Administration (FDA) has ...

WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in ...

On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing application for Calquence (acalabrutinib) for adult patients with previously ...

(RTTNews) - AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application for Enhertu in combination with pertuzumab has been accepted and granted Priority Review in the US for the first ...

AstraZeneca shares rallied on Wednesday after the U.K.-based pharmaceuticals giant and its Japanese partner said the Food and Drug Administration was reviewing one of its drugs to treat breast cancer.

Aug 15 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Thursday the U.S. Food and Drug Administration (FDA) has granted its blockbuster cancer drug Imfinzi a priority review for patients with ...